Impact and Management of hepatitis B and hepatitis C virus co-infection in HIV patients

作者: Vikas Singla , Ramesh Kumar , Subrat k Kacharya

DOI:

关键词:

摘要: Individuals at risk of HIV are concomitantly acquiring parenterally or sexually transmitted viruses, including HBV and HCV. After the introduction highly active antiretroviral therapy (ART), liver disease has emerged as a major cause morbidity mortality in HIV-infected persons. HBV, HCV share common routes transmission, but differential efficiency these viruses to types exposures underlies difference their prevalence by geographic region. Coinfection alters natural history each peculiar way; furthermore coinfection with viral hepatitis may complicate delivery ART increasing drug-related hepatoxicity impacting selection specific agents (e.g., those dually against HBV). The treatment co-infection is complex because drug(s) used is/are associated drug-resistance, cross-resistance, hepatotoxicity suboptimal response. aim achieve long-term sustained (HBV) suppression. should be treated coinfected patients elevated DNA significant hepatic fibrosis (Metavir score = A2 F2). threshold for initiation lower than monoinfection. Anti also considered receiving irrespective load fibrosis, order prevent immune reconstitution. Selection depends on whether require only both HIV. In requiring treatment, drugs dual antiviral activity not avoid early resistance. When meet criteria included anti-retroviral regimen. Treatment monitored measuring ALT levels 3 6 monthly. required duration induviduals known possibly life long. Every person compensated chronic treatment. However, avoided decompensated cirrhosis presence opportunistic infection. CD4 counts <200 cells/il and/or plasma HIV-RNA above 100,000 copies/mI, it better consider anti before standard pegylated interferon alfa-2a (Pegasys) -2b (Peg-Intron) plus ribavirin 48 weeks. Several studies have shown an overall vwal response rate 14% 29% genotype 1 53% 73% genotypes 2 3. other concern drug interaction retroviral necessitating avoidance certain from persons denied HAART evaluated transplantation. Finally, management responding standared known.

参考文章(126)
C Brechot, F Carnot, H Zylberberg, G Pialoux, S Pol, F Dubois, J Jiang, P Berthelot, F Driss, Alpha-interferon for chronic active hepatitis B in human immunodeficiency virus-infected patients. Gastroenterologie Clinique Et Biologique. ,vol. 20, pp. 968- 971 ,(1996)
Massimo Puoti, Monica Airoldi, Raffaele Bruno, Barbara Zanini, Angiola Spinetti, Chiara Pezzoli, Andrea Patroni, Francesco Castelli, Paolo Sacchi, Gaetano Filice, Giampiero Carosi, None, Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. Aids Reviews. ,vol. 4, pp. 27- 35 ,(2002)
Shanmugam Saravanan, Vijayakumar Velu, Nagalingeswaran Kumarasamy, Subhadra Nandakumar, Kailapuri Gangatharan Murugavel, Pachamuthu Balakrishnan, Solomon Suniti, Sadras Panchatcharam Thyagarajan, None, Coinfection of hepatitis B and hepatitis C virus in HIV-infected patients in south India. World Journal of Gastroenterology. ,vol. 13, pp. 5015- 5020 ,(2007) , 10.3748/WJG.V13.I37.5015
María J Perez-Elías, Fernando Dronda, Rafael Bárcena, Enrique Navas, Jose L Casado, Carmen Quereda, Santiago Moreno, Alfonso Muriel, Antonio Antela, Leonor Moreno, Ana Moreno, High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antiviral Therapy. ,vol. 9, pp. 133- 138 ,(2004)
Swati Gupta, Sarman Singh, Hepatitis B and C virus co-infections in human immunodeficiency virus positive North Indian patients World Journal of Gastroenterology. ,vol. 12, pp. 6879- 6883 ,(2006) , 10.3748/WJG.V12.I42.6879
Luz Martin-Carbonero, Javier Garcia-Samaniego, Juan Gonzalez-Lahoz, Ivana Maida, Nuria Camino, Pablo Barreiro, Vincent Soriano, Miriam Romero, Marina Nunez, Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Antiviral Therapy. ,vol. 9, pp. 505- 509 ,(2004)
Philip S. Rosenberg, Kenneth E. Sherman, Angelos Hatzakis, Michael M. Lederman, Louis M. Aledort, Margaret W. Hilgartner, Gilbert C. White, Titica Mandalaki, Marilyn Manco-Johnson, Liliana Preiss, Barbara L. Kroner, Cindy Leissinger, Alan R. Cohen, Craig M. Kessler, Naomi L. C. Luban, Donna DiMichele, Anne L. Angiolillo, James J. Goedert, Philippe de Moerloose, M. Elaine Eyster, End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood. ,vol. 100, pp. 1584- 1589 ,(2002) , 10.1182/BLOOD.V100.5.1584.H81702001584_1584_1589
C Padmapriyadarsini, J Chandrabose, L Victor, LE Hanna, N Arunkumar, Soumya Swaminathan, Hepatitis B or hepatitis C co-infection in individuals infected with human immunodeficiency virus and effect of anti-tuberculosis drugs on liver function Journal of Postgraduate Medicine. ,vol. 52, pp. 92- 96 ,(2006)
Farees N, Poduri Cd, Hussain Mm, Aejaz Habeeb M, Chandra M, Khaja Mn, Habibullah Cm, Prevalence, risk factors and genotype distribution of HCV and HBV infection in the tribal population: a community based study in south India. Tropical gastroenterology : official journal of the Digestive Diseases Foundation. ,vol. 24, pp. 193- 195 ,(2003)